• Company
• Keytruda's sales have been leading for two consecutive years
• by Chon, Seung-Hyun Nov 26, 2021 05:54am

• Policy
• Winner of pricing suits will be compensated for damages
• by Kim, Jung-Ju Nov 26, 2021 05:54am

• Company
• Will the sale of impurity Losartan be okay?
• by Kim, Jin-Gu Nov 26, 2021 05:53am

• Policy
• Cost bearer in debate ahead recall of some losartan products
• by Lee, Tak-Sun Nov 26, 2021 05:53am

• Policy
• All agreed to the legislation of the CSO reporting system
• by Lee, Jeong-Hwan Nov 26, 2021 05:53am

• Company
• Tabrecta and Tepmetko are approved simultaneously for NSCLC
• by Nov 25, 2021 05:56am

• Company
• Shionogi's stock price is soaring
• by Eo, Yun-Ho Nov 25, 2021 05:56am

• Product
• Organon aims to resume Cozaar XQ supply from 2022 Q1
• by Nov 25, 2021 05:56am

• Policy
• Losartan, which has a high proportion of consignment
• by Lee, Tak-Sun Nov 25, 2021 05:55am

• Product
• α-GPC can't be replaced with other drugs in the field
• by Kim, Jin-Gu Nov 25, 2021 05:55am